Drug intelligence / Profile preview

SYSA1901

Development stage: Phase 3
Lead developer: CSPC ZhongQi Pharmaceutical Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SYSA1901 is a biosimilar candidate of pertuzumab, a recombinant humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). Developed by CSPC Pharmaceutical Group, SYSA1901 is designed to inhibit the dimerization of HER2 with other HER family receptors, particularly HER3, which is a critical step in the activation of signaling pathways that promote tumor growth and survival. It is currently being evaluated in Phase III clinical trials for the neoadjuvant treatment of early-stage or locally advanced HER2-positive breast cancer, where it is compared for efficacy and safety equivalence to the reference product, Perjeta.

Other names: pertuzumab biosimilar

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on SYSA1901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYSA1901.

Explore the full profile